AI Is Becoming the Force Multiplier Biotech Needs
-

Modern biotech has the tools to design drugs and edit genes — but the industry has long faced a talent bottleneck. Thousands of rare diseases remain untreated because there simply aren’t enough skilled scientists to tackle them.
AI is changing that. Companies like Insilico Medicine are training large language models to perform multiple drug discovery tasks at once, from identifying disease targets to nominating candidate molecules — all with superhuman speed and accuracy.
The goal? Pharmaceutical superintelligence that can explore neglected diseases, repurpose existing drugs, and accelerate therapies for conditions like ALS. By automating labor-intensive steps, AI lets humans focus on insight and innovation, potentially unlocking cures for thousands of diseases that have been left behind.